1. Home
  2. ATER vs NEUP Comparison

ATER vs NEUP Comparison

Compare ATER & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aterian Inc.

ATER

Aterian Inc.

HOLD

Current Price

$0.58

Market Cap

7.0M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.34

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ATER
NEUP
Founded
2014
1996
Country
United States
United States
Employees
N/A
8
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
23.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ATER
NEUP
Price
$0.58
$4.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
63.9K
23.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
55.77
N/A
EPS
N/A
N/A
Revenue
$99,045,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$3.65
52 Week High
$3.50
$21.31

Technical Indicators

Market Signals
Indicator
ATER
NEUP
Relative Strength Index (RSI) 39.48 55.39
Support Level $0.52 $3.99
Resistance Level $0.74 $4.56
Average True Range (ATR) 0.06 0.17
MACD 0.00 0.02
Stochastic Oscillator 27.59 66.08

Price Performance

Historical Comparison
ATER
NEUP

About ATER Aterian Inc.

Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: